| Filed On | Filing |
|---|---|
| 10 Nov 2026 | 10-Q |
| 10 Nov 2026 |
8-K: Results of Operations and Financial Condition
Preliminary data from the ongoing Phase 1b/2 study of TH103 in nAMD is now expected in 2H 2027 |
| 26 Oct 2026 | SCHEDULE 13G |
| 28 Aug 2026 |
Form 4: Vandekop Amy O'Leary, VP, Corporate Controller
Granted 10,000 Stock Option (Right to Buy) |
| 11 Aug 2026 | 10-Q |
| 11 Aug 2026 |
8-K: Results of Operations and Financial Condition
Patient dosing is ongoing in the Phase 1b/2 study of TH103; preliminary data anticipated in 1H 2027 |
| 03 Aug 2026 |
Form 4: Keating Laurie, Director
Granted 18,000 Stock Option (Right to Buy) |
| 03 Aug 2026 |
Form 3: Keating Laurie, Director
No securities owned |
| 27 Jul 2026 |
Form 3: Vandekop Amy O'Leary, See Remarks
Holds 948 shares of Common Stock |
| 20 Jul 2026 |
Form 4: Bayko Liisa Ann, Chief Financial Officer
Granted 220,000 Stock Option (Right to Buy) |
| 20 Jul 2026 |
Form 3: Bayko Liisa Ann, Chief Financial Officer
No securities owned |
| 20 Jul 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
THIS EMPLOYMENT AGREEMENT (the “Agreement”) is made as of July 7, 2026 by and between Kalaris Therapeutics, Inc. (the “Company”), and Liisa Bayko (the “Executive”) (together, the “Parties”). |
| 17 Jul 2026 |
8-K: Regulation FD Disclosure; Other Events
Forward-Looking Statements & Disclaimer This presentation contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as am... |
| 06 Jul 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 04 Jun 2026 |
Form 4: Jovan-Embiricos Morana, Director
Granted 9,000 Stock Option (Right to Buy) |
| 04 Jun 2026 |
Form 4: Ferrara Napoleone, Director
Granted 9,000 Stock Option (Right to Buy) |
| 04 Jun 2026 |
Form 4: Hallal David, Director
Granted 9,000 Stock Option (Right to Buy) |
| 04 Jun 2026 |
Form 4: Akkaraju Srinivas, Director
Granted 9,000 Stock Option (Right to Buy) |
| 04 Jun 2026 |
Form 4: Dybbs Michael, Director
Granted 9,000 Stock Option (Right to Buy) |
| 04 Jun 2026 |
Form 4: Adamis Anthony P, Director
Granted 9,000 Stock Option (Right to Buy) |
Loading...